Results of RIC allogeneic hematopoietic transplantation for CLL
| N . | RIC regimen . | Median age, y (range) . | Chemorefractory, % . | Prior auto-HCT, % . | Donor, % related . | NRM, % . | Grade II-IV aGVHD, % . | Extensive cGVHD . | Survival, % OS and PFS . | Reference (year) . |
|---|---|---|---|---|---|---|---|---|---|---|
| 82 | Flu-LDTBI | 56 (42-72) | 87 | 4 | 63 | 23 (5 y) | 55 related, 66 unrelated | 49 related, 53 unrelated | 50 OS, 39 PFS (5 y) | Sorror et al43 (2008) |
| 39 | Flu-Cy-Ritux | 57 (34-70) | 28 | — | 90 | 28 (4 y) | 45 | 58 | 48 OS, 44 PFS (4 y) | Khouri et al52 (2007) |
| 90 | Flu-Cy based ± ATG | 53 (27-65) | 24 (47 FR) | 32 | 39 | 23 (3 y) | 34 | 52 | 66 OS, 42 PFS (3 y) | Dreger et al71 (2008) |
| 41 | Flu-Mel-Alem | 52 (37-64) | 15 (43 FR) | 17 | 78 | 28 (3 y) | 37 | 10 | 65 OS, 39 PFS (3 y) | Delgado et al53 (2008) |
| 21 | Flu-Mel | 54 (34-64) | 38 (29 FR) | 10 | 86 | 34 (3 y) | 57 | 48 | 57 OS, 47 PFS (3 y) | Delgado et al53 (2008) |
| 30 | Flu-Bu-ATG | 50 (12-63) | 46 | 10 | 50 | 16 (2 y) | 56 | 21 | 72 OS, 67 PFS (2 y) | Schetelig et al48 (2003) |
| 43 | Flu-Bu | 53 (35-67) | 57 | 22 | 33 | 17 (2 y) | 34 | 38 | 54 OS, 34 PFS (2 y) | Brown et al51 (2006) |
| N . | RIC regimen . | Median age, y (range) . | Chemorefractory, % . | Prior auto-HCT, % . | Donor, % related . | NRM, % . | Grade II-IV aGVHD, % . | Extensive cGVHD . | Survival, % OS and PFS . | Reference (year) . |
|---|---|---|---|---|---|---|---|---|---|---|
| 82 | Flu-LDTBI | 56 (42-72) | 87 | 4 | 63 | 23 (5 y) | 55 related, 66 unrelated | 49 related, 53 unrelated | 50 OS, 39 PFS (5 y) | Sorror et al43 (2008) |
| 39 | Flu-Cy-Ritux | 57 (34-70) | 28 | — | 90 | 28 (4 y) | 45 | 58 | 48 OS, 44 PFS (4 y) | Khouri et al52 (2007) |
| 90 | Flu-Cy based ± ATG | 53 (27-65) | 24 (47 FR) | 32 | 39 | 23 (3 y) | 34 | 52 | 66 OS, 42 PFS (3 y) | Dreger et al71 (2008) |
| 41 | Flu-Mel-Alem | 52 (37-64) | 15 (43 FR) | 17 | 78 | 28 (3 y) | 37 | 10 | 65 OS, 39 PFS (3 y) | Delgado et al53 (2008) |
| 21 | Flu-Mel | 54 (34-64) | 38 (29 FR) | 10 | 86 | 34 (3 y) | 57 | 48 | 57 OS, 47 PFS (3 y) | Delgado et al53 (2008) |
| 30 | Flu-Bu-ATG | 50 (12-63) | 46 | 10 | 50 | 16 (2 y) | 56 | 21 | 72 OS, 67 PFS (2 y) | Schetelig et al48 (2003) |
| 43 | Flu-Bu | 53 (35-67) | 57 | 22 | 33 | 17 (2 y) | 34 | 38 | 54 OS, 34 PFS (2 y) | Brown et al51 (2006) |
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; Flu, fludarabine; LDTBI, low-dose total body irradiation; Cy, cyclophosphamide; Ritux, rituximab; ATG, thymoglobulin; Mel, melphalan; Alem, alemtuzumab; Bu, busulfan; FR, fludarabine-refractory; and —, not stated.